Hirota et al., 2016 - Google Patents
Chemically modified interleukin-6 aptamer inhibits development of collagen-induced arthritis in cynomolgus monkeysHirota et al., 2016
View PDF- Document ID
- 887431535637128676
- Author
- Hirota M
- Murakami I
- Ishikawa Y
- Suzuki T
- Sumida S
- Ibaragi S
- Kasai H
- Horai N
- Drolet D
- Gupta S
- Janjic N
- Schneider D
- Publication year
- Publication venue
- Nucleic acid therapeutics
External Links
Snippet
Interleukin-6 (IL-6) is a potent mediator of inflammatory and immune responses, and a validated target for therapeutic intervention of inflammatory diseases. Previous studies have shown that SL1026, a slow off-rate modified aptamer (SOMAmer) antagonist of IL-6 …
- 102000004889 Interleukin-6 0 title abstract description 145
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hirota et al. | Chemically modified interleukin-6 aptamer inhibits development of collagen-induced arthritis in cynomolgus monkeys | |
Sivamani et al. | Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring | |
EP3111954B1 (en) | Methods of treating ankylosing spondylitis using anti-il-17 antibodies | |
US11008393B2 (en) | Pharmaceutical compositions comprising a polypeptide that binds to IL-6 | |
Taylor | Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases | |
EP3119806B1 (en) | Il-21 antibodies | |
JP5834004B2 (en) | Methods and compositions for lupus treatment | |
RU2714919C2 (en) | Gm-csf-neutralizing antibodies for use in treating rheumatoid arthritis or as analgesics | |
JP2015524793A (en) | Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3, and anti-CXCR5 agonists for inflammation inhibition | |
TW201429988A (en) | Antibodies to interleukin-6 and uses thereof | |
US20180113139A1 (en) | Methods and compositions for diagnosing and treating inflammatory bowel disorders | |
Liu et al. | Interleukin-6 in rheumatoid arthritis-from the laboratory to the bedside | |
Zhou et al. | Plasmacytoid dendritic cells promote the pathogenesis of sjögren's syndrome | |
JP2023542878A (en) | LOU064 for treating multiple sclerosis | |
AU2008324800B2 (en) | Methods of treating scleroderma | |
Berkhout et al. | Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment | |
WO2018029182A1 (en) | Il-6r single variable domain antibodies for treatment of il-6r related diseases | |
TW202106712A (en) | Methods of diagnosis and treatment of rheumatoid arthritis | |
Reimund et al. | Anti-Tumor Necrosis Factor-alpha (TNF-α) Treatment Strategies in Crohn's Disease | |
AU2014259523B2 (en) | Methods of treating psoriatic arthritis using IL-17 antagonists | |
Hirabayashi et al. | The role of tocilizumab in the treatment of rheumatoid arthritis | |
Sozeri et al. | Canakinumab: new treatment choice for systemic juvenile idiopathic arthritis | |
Ellies et al. | Adipose tissue macrophage Diet-induced obesity Free fatty acid GPCR HFD | |
WO2017064564A2 (en) | Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody | |
JP2019515902A (en) | Functional plasticity of ILC2, immunity, and COPD |